REAL-WORLD OUTCOMES WITH MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA ACCORDING TO SMOKING HISTORY AND COPD STATUS AT ENROLLMENT: REALITI-A POST HOC ANALYSIS

被引：0
|
作者：
Bagnasco, Diego
Hill, David G.
Welte, Tobias
Chaudhuri, Rekha
Price, Robert
Howarth, Peter
机构：
来源：
CHEST | 2023年 / 164卷 / 04期
关键词：
D O I：
10.1016/j.chest.2023.07.102
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：75A / 76A
页数：2
相关论文
共 50 条
  • [1] Real-world mepolizumab outcomes in severe asthma: REALITI-A post hoc analysis by exacerbation history
    Bagnasco, Diego
    Lougheed, Diane
    Subramanian, Vijay
    Clifton, Ian J.
    Price, Robert G.
    Howarth, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [2] Real-World mepolizumab outcomes in severe asthma; REALITI- A post hoc analysis by exacerbation history
    Bagnasco, D.
    Lougheed, D.
    Subramanian, V
    Clifton, I
    Price, R.
    Howarth, P.
    Skowasch, D.
    PNEUMOLOGIE, 2024, 78 : S10 - S11
  • [3] Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A
    Liu, Mark
    Bagnasco, Diego
    Matucci, Andrea
    Pilette, Charles
    Price, Robert
    Maxwell, Aoife
    Alfonso-Cristancho, Rafael
    Jakes, Rupert
    Lee, Jason
    Cheema, Amarjit
    Howarth, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB20 - AB20
  • [4] The impact of mepolizumab self-administration on real-world outcomes in patients with severe asthma: Post hoc analysis of REALITI-A at 2 years
    Canonica, G. W.
    Demetriou, L.
    Schleich, F.
    Pelaia, G.
    Bernstein, D.
    Lee, F. E. H.
    Price, R. G.
    Howarth, P.
    ALLERGY, 2023, 78 : 185 - 186
  • [5] Real-world outcomes of patients with severe asthma treated with mepolizumab by baseline inhaled corticosteroid dose: Post hoc analysis of realiti-a at 2 years
    Smith, A.
    Patel, M.
    Caruso, C.
    Pilette, C.
    Welte, T.
    Alfonso-Cristancho, R.
    Price, R. G.
    Howarth, P.
    ALLERGY, 2023, 78 : 50 - 51
  • [6] Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
    Harrison, Tim
    Canonica, Giorgio Walter
    Chupp, Geoffrey
    Lee, Jason
    Schleich, Florence
    Welte, Tobias
    Valero, Antonio
    Gemzoe, Kim
    Maxwell, Aoife
    Joksaite, Sandra
    Yang, Shibing
    Howarth, Peter
    Van Dyke, Melissa K.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (04)
  • [7] Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility
    Lee, Jason
    Pollard, Stephen
    Liu, Mark
    Schleich, Florence
    Pelaia, Girolamo
    Almonacid, Carlos
    Heaney, Liam
    Chaudhuri, Rekha
    Alfonso-Cristancho, Rafael
    Jakes, Rupert
    Price, Robert
    Maxwell, Aoife
    Howarth, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB21 - AB21
  • [8] Real-world outcomes with mepolizumab in patients with severe asthma and comorbid anxiety/depression: REALITI-A at 2 years
    Chaudhuri, Rekha
    Liu, Mark C.
    Bagnasco, Diego
    Matucci, Andrea
    Pilette, Charles
    Price, Robert G.
    Demetriou, Lydia
    Howarth, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [9] National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study
    Lee, J. K.
    Schleich, F.
    Canonica, G. W.
    Munoz, X.
    Chaudhuri, R.
    Lee, F. E.
    Howarth, P.
    Price, R. G.
    Yang, S.
    Jakes, R. W.
    Maxwell, A.
    Cristancho, R. Alfonso
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [10] International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A
    Pilette, Charles
    Canonica, Giorgio Walter
    Chaudhuri, Rekha
    Lee, F. Eun-Hyung
    Lee, Jason Kihyuk
    Sanchez, Carlos Almonacid
    Alfonso-Cristancho, Rafael
    Jakes, Rupert
    Maxwell, Aoife
    Price, Robert
    Howarth, Peter
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 566 - 566
12345